Prestige Brands Expects OTC Assets Will Shake Loose From M&A Activity
This article was originally published in The Tan Sheet
Executive Summary
“If you looked at it based on history,” consolidation has created opportunities to acquire OTC brands, says Prestige Brands CEO Matthew Mannelly. The firm’s interest in adding brands is “stronger than ever,” he adds.
You may also be interested in...
Prestige Consumer Opens Its FY2023 With Revenue Thirst Quenched By Hydralyte International Sales
Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.
In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims
Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.
Genomma Refuses To Raise Price, Drops Prestige Bid
Genomma drops its unsolicited offer because it was unwilling to meet Prestige’s demand for a higher price. The Mexican firm said it secured funding and met other milestones Prestige insisted on.